Dr. Gluck's submission to True North Stories

[Guest guest]

Dr. Gluck emailed me that he had submitted his 300 words on the LDN to

true north stories. I asked him if I could have a copy to show the

group, but he declined. I pressed him, saying if he submitted it

maybe others in the group would do likewise.

Herewith his reply:

___________________________________________

Jeez! You are tough to deal with!

I am not proud of this -- but it's all that I could do with 300 words

(and their theme):

[sent online on 12/21/08]

In 1986, a Harvard-trained physician friend of mine, Dr. Bernard

Bihari, discovered that a low dosage of the pure narcotic-blocker,

FDA-approved naltrexone, strengthens the immune system. Thus, low dose

naltrexone (LDN) can relieve most patients of further progression from

HIV infection or any autoimmune disease or even, in many cases, of

cancer. Sadly, in the years that followed, he found that no

pharmaceutical company was interested in pursuing this discovery!

I am a Board-certified specialist in both Internal Medicine and

Preventive Medicine. Through my website (www.ldninfo.org), I have

spent the last decade devoting each day to bringing the attention of

physicians and the general public to this discovery, which is truly

unprecedented and so badly needed.

LDN is simply an off-label use of a safe medication. No one is

counting on making money from it, since the original large-dosage

naltrexone is a generic drug which is well past its patent coverage

and is available at low cost. And without large pharmaceutical

backing, FDA approval is unavailable.

Yet, persuaded by the insistent reports from many grateful LDN users,

researchers have finally begun small clinical studies. Penn State 's

Hershey Medical Center in 2007 published a study that describes low

dose naltrexone as a " safe and effective " treatment for the classic

autoimmune disorder, Crohn's disease. Neurologists at the University

of California in San Francisco have announced the successful results

of a double-blind trial of LDN for multiple sclerosis (MS).

Neurological researchers in Milan, published this year their positive

six-month study of LDN treatment for the heretofore untreatable

Primary Progressive MS!

In the face of these new clinical trial results, my intense hope is

that the government might recognize the important potential

contributions to both our country's and the world's health and health

costs, and act to formally approve the use of LDN.